First-Trimester SARS-CoV-2 Infection: Clinical Presentation, Inflammatory Markers, and Obstetric Outcomes
Fetal Diagnosis and Therapy · 2022 · 49 (3) · 67-76
DOI: 10.1159/000523974 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Fetal Diagnosis and Therapy, online erschienen am 09.03.2022. Verfasst von Cristina Trilla und 6 weiteren Autor:innen. Beteiligte Einrichtung: Maternal and Fetal Medicine Unit, Obstetrics and Gynecology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. Hauptthemen laut MEDLINE: COVID-19, Pre-Eclampsia. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objective
Second- and third-trimester SARS-CoV-2 infections may have an increased risk of obstetric complications. However, data on first-trimester infections are scarce. We sought to characterize the clinical and inflammatory presentations and pregnancy outcomes of first-trimester infections.
Methods
A population-based multicenter study including 817 singleton pregnancies with SARS-CoV-2 serologic testing at 8–14 weeks between March and May 2020. Blood count, uterine artery Doppler, and pregnancy-associated plasma protein A (PAPP-A) were performed in all women. Placental growth factor (PlGF), soluble fms-like tyrosine kinase 1 (sFlt-1), IL-6, and ferritin were determined in positive women. Obstetric outcomes were evaluated.
Results
The prevalence of first-trimester infection was 15.2% (n = 124). 72.6% of positive women were asymptomatic. Symptomatic women had higher rates of lymphopenia (1.91 × 109/L vs. 2.16 × 109/L, p = 0.017) and increased levels of IL-6 (9.1% vs. 1.2%, p = 0.051), but lower rates of decreased ferritin (6.3% vs. 19.8%, p = 0.015). PAPP-A was higher in symptomatic women compared with asymptomatic and negative women (1.44 [IQR 0.90–1.82] vs. 1.08 [IQR 0.66–1.61] p = 0.014, vs. 1.08 [IQR 0.77–1.55] p = 0.019, respectively). Obstetric outcomes were not increased.
Conclusions
First-trimester SARS-CoV-2 infections are mostly asymptomatic, with a mild increase of inflammatory markers in symptomatic women. Obstetric complications were not increased, but PAPP-A levels were higher in symptomatic women.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Maternal and Fetal Medicine Unit, Obstetrics and Gynecology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
- Faculty of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.
- Institut d'Investigació Biomèdica Sant Pau - IIB Sant Pau, Barcelona, Spain.
- Biochemistry Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
- Department of Maternal-Fetal Medicine, BCNatal, Barcelona Center for Maternal-Fetal and Neonatal Medicine, Hospital Sant Joan de Déu and Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.
- Institut de Recerca Sant Joan de Deu, Barcelona, Spain.
Zitieren
APA
Trilla, C., Mora, J., Crovetto, F., Crispi, F., Gratacos, E., Llurba, E., & KidsCorona Pregnancy COVID-19 Group (2022). First-Trimester SARS-CoV-2 Infection: Clinical Presentation, Inflammatory Markers, and Obstetric Outcomes. Fetal Diagnosis and Therapy, 49(3), 67-76. https://doi.org/10.1159/000523974
Vancouver
Trilla C, Mora J, Crovetto F, Crispi F, Gratacos E, Llurba E, et al. First-Trimester SARS-CoV-2 Infection: Clinical Presentation, Inflammatory Markers, and Obstetric Outcomes. Fetal Diagnosis and Therapy. 2022;49(3):67-76. doi:10.1159/000523974
BibTeX
@article{Trilla2022,
author = {Trilla, Cristina and Mora, Josefina and Crovetto, Francesca and Crispi, Fàtima and Gratacos, Eduard and Llurba, Elisa and KidsCorona Pregnancy COVID-19 Group, KidsCorona Pregnancy COVID-19 Group},
title = {First-Trimester SARS-CoV-2 Infection: Clinical Presentation, Inflammatory Markers, and Obstetric Outcomes},
journal = {Fetal Diagnosis and Therapy},
year = {2022},
volume = {49},
number = {3},
pages = {67--76},
doi = {10.1159/000523974}
}
EUVIMED